Form 4: CRISPR CFO Granted 16,500 Stock Options

CRISPR Therapeutics AG's Chief Financial Officer, Raju Prasad, was granted 16,500 stock options with an exercise price of $67.74, vesting over 48 months.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG (CRSP), was granted 16,500 stock options.
• The options have an exercise price of $67.74 per share.
• The grant date for these options was October 3, 2025.
• The shares will vest in 48 equal monthly installments, with the first vesting date on November 3, 2025.
• The options expire on October 3, 2035.
• The options were acquired with a transaction code 'A', indicating an acquisition.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive aligns management's interests with shareholder value creation, reflecting standard executive compensation practices.

Positives

• The grant of 16,500 stock options to the Chief Financial Officer, Raju Prasad, aligns management's long-term interests with shareholder value creation.
• Equity compensation is a standard practice to incentivize executive performance and retention.

Negatives

• No direct negative implications are present in this routine executive compensation disclosure.

Risks

• No specific risks are disclosed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The stock options are structured to vest over 48 equal monthly installments, with the first vesting on November 3, 2025, indicating a long-term incentive for the Chief Financial Officer.

Industry Context

The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation, such as stock option grants, is a common practice for executive incentives across the biotechnology and pharmaceutical industries.
• The vesting schedule of 48 equal monthly installments is a typical long-term incentive structure designed to retain executives and align their performance with company growth over several years.
• The exercise price being set at the market price on the grant date is standard for incentive stock options.

Stakeholder Impact

• Shareholders may benefit from increased alignment of management's interests with long-term company performance due to equity-based compensation.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting November 3, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a key executive, which is a standard component of executive compensation. It does not provide new information that would fundamentally alter the investment thesis for CRISPR Therapeutics AG, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Form 4, Insider Transaction, Raju Prasad, CFO, Equity Compensation, Executive Compensation